You have 8 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

hormone refractory prostate cancer (HRPC)

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Prostate Cancer Trial in United States (Vinflunine)

Completed
Has Results
  • Prostate Cancer
  • Fort Myers, Florida
  • +11 more
Dec 14, 2021

Hormone Refractory Prostate Cancer Trial in United States (LBH589)

Terminated
  • Hormone Refractory Prostate Cancer
  • Boston, Massachusetts
  • +4 more
Dec 16, 2020

Hormone Refractory Prostate Cancer Trial in United States (Docetaxel, TroVax)

Terminated
  • Hormone Refractory Prostate Cancer
  • San Bernardino, California
  • +6 more
Oct 8, 2020

Prostate Cancer Trial in Los Angeles (carboplatin, paclitaxel)

Completed
Has Results
  • Prostate Cancer
  • Los Angeles, California
    Jonsson Comprehensive Cancer Center at UCLA
Aug 17, 2020

Biomarkers of Response to Taxotere in HRPC. ICORG 08-08, V2

Completed
  • Metastatic Cancer
  • Prostate Cancer
  • Dublin, Ireland
  • +4 more
Nov 16, 2020

Metastatic Hormone-Sensitive Prostate Cancer Trial (Rezvilutamide, Rezvilutamide plus abiraterone, Continue previous treatment)

Not yet recruiting
  • Metastatic Hormone-Sensitive Prostate Cancer
  • (no location specified)
Nov 10, 2023

Hormone-refractory Prostate Cancer Trial (AMX-500)

Not yet recruiting
  • Hormone-refractory Prostate Cancer
  • (no location specified)
Aug 11, 2023

Refractory Cancer Trial in Hamburg (BIBW 2992 (Afatinib))

Terminated
  • Refractory Cancer
  • BIBW 2992 (Afatinib)
  • Hamburg, Germany
    University Medical Center Hamburg-Eppendorf
Jun 29, 2022

Learn More About How Safe Darolutamide is Under Real-world

Not yet recruiting
  • Metastatic Hormone-sensitive Prostate Cancer (mHSPC)
  • No Intervention
  • Multiple Locations, Japan
    Many Locations
Aug 24, 2023

Metastatic Hormone Refractory Prostate Cancer Trial in Saint Louis (Cabozantinib, Nivolumab, Abiraterone acetate)

Recruiting
  • Metastatic Hormone Refractory Prostate Cancer
  • Saint Louis, Missouri
    Washington University School of Medicine
Jun 6, 2022

Metastatic Prostate Cancer, Hormone Sensitive Prostate Cancer, Chemo Effect Trial in Nanjing (Docetaxel, Rezvilutamide)

Recruiting
  • Metastatic Prostate Cancer
  • +2 more
  • Nanjing, Jiangsu, China
    Urology dpt, First Affiliated Hospital of Nanjing Medical Univer
Aug 2, 2023

Apalutamide in Metastatic Hormone Sensitive Prostate Cancer

Not yet recruiting
  • Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)
    • Cardiff, United Kingdom
    • +4 more
    Aug 25, 2023

    Prostate Cancer Trial (ADT, Enzalutamide, Talazoparib)

    Not yet recruiting
    • Prostate Cancer
    • (no location specified)
    May 15, 2023

    Prostate Cancer Trial in Baltimore (DFMO, testosterone cypionate, Luteinizing hormone-releasing hormone (LHRH) analogue)

    Not yet recruiting
    • Prostate Cancer
    • Baltimore, Maryland
      Johns Hopkins University: Sidney Kimmel Comprehensive Cancer Cen
    Sep 22, 2023

    Androgen-Independent Prostatic Cancer, Androgen-Independent Prostatic Tumors, Prostate Cancer Recurrent Trial (lorigerlimab,

    Not yet recruiting
    • Androgen-Independent Prostatic Cancer
    • +8 more
    • lorigerlimab
    • +2 more
    • (no location specified)
    May 4, 2023

    Prostate Adenocarcinoma, Stage IIB Prostate Cancer AJCC v8, Stage IIC Prostate Cancer AJCC v8 Trial in Houston (drug,

    Completed
    Has Results
    • Prostate Adenocarcinoma
    • +4 more
    • Abiraterone Acetate
    • +4 more
    • Houston, Texas
      M D Anderson Cancer Center
    Jul 14, 2022

    Oligometastatic Prostate Cancer Trial in New York (Quemliclustat, Etrumadenant, Zimberelimab)

    Not yet recruiting
    • Oligometastatic Prostate Cancer
    • New York, New York
      Columbia University Irving Medical Center / NewYork-Presbyterian
    Jun 14, 2023

    Prostate Cancer, Radiotherapy Side Effect, Metastatic Cancer Trial in Umeå (Moderate hypo-fractionation,

    Recruiting
    • Prostate Cancer
    • +2 more
    • Moderate hypo-fractionation
    • Ultra-hypo-fractionation
    • Umeå, Sweden
      Cancercenter University hospital of Umeå
    Nov 1, 2022

    Prostatic Tumors Trial in Bronx (Abiraterone Acetate, Prednisone)

    Active, not recruiting
    • Prostatic Neoplasms
    • Bronx, New York
      Montefiore Medical Center
    Sep 22, 2022

    Prostate Cancer Trial in United States (Docetaxel, Docetaxel and GM-CSF)

    Completed
    Has Results
    • Prostate Cancer
    • San Francisco, California
    • +3 more
    Oct 29, 2019

    Prostate Cancer Trial in Chicago (Docetaxel, ADT, Abiraterone)

    Not yet recruiting
    • Prostate Cancer
    • Chicago, Illinois
      Northwestern University
    Sep 27, 2023

    Development ofTherapeutic Education Program for Metastatic

    Recruiting
    • Prostate Cancer
    • Focus group creation
    • Workshop
    • Nîmes, France
      CHU de Nimes
    Sep 20, 2022

    Hormone-Resistant Prostate Cancer, Metastatic Prostate Carcinoma, Prostate Carcinoma Metastatic in the Bone Trial in United

    Recruiting
    • Hormone-Resistant Prostate Cancer
    • +3 more
    • Ann Arbor, Michigan
    • +3 more
    Feb 2, 2023

    Prostate Cancer, Refractory Cancer, Castration Resistant Prostatic Cancer Trial in Winston-Salem (Omeprazole 80 mg twice daily)

    Recruiting
    • Prostate Cancer
    • +2 more
    • Omeprazole 80 mg twice daily
    • Winston-Salem, North Carolina
      Wake Forest Baptist Comprehensive Cancer Center
    Jan 5, 2023

    Oligometastatic Hormone Sensitive Prostate Cancer Trial in Florence (SBRT on all sites of metastatic disease+Apalutamide)

    Not yet recruiting
    • Oligometastatic Hormone Sensitive Prostate Cancer
    • SBRT on all sites of metastatic disease+Apalutamide
    • Florence, Italy
      AOU Careggi Radiation Oncology Unit
    Jan 29, 2023